首页/数据集/Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

NIAID Data Ecosystem2026-03-07 收录

造血干细胞动员

血液肿瘤治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2158857 数据链接链接失效反馈

官方服务：

资源简介：

This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.

应用场景：

创建时间：

2011-07-15

造血干细胞动员

多发性骨髓瘤

Introduction: In patients with a clinical indication for autologous hematopoietic stem cell transplantation (ASCT) sufficient mobilization of CD34+ precursor cells into peripheral blood is essential t

DataCite Commons2023-10-24 更新110

Molecular phenotype of G-CSF- or pegylated G-CSF-mobilized CD34+ cells. Homo sapiens

造血干细胞动员

CD34+细胞分子表型

Peripheral blood stem and progenitor cells (PBSC) are widely used for autologous and allogeneic hematopoietic stem cell transplantation. PBSC can be mobilized into the peripheral blood using cytokines

NIAID Data Ecosystem50

G-CSF plus AMD3100 mobilization in adult patients with beta-thalassemia results in effective mobilization of CD34+ cells with primitive signatures

造血干细胞动员

β-地中海贫血基因治疗

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic progenitors stem cells (HPSC) with high repopulating capacity and mobilization is the opt

NIAID Data Ecosystem40

Hairy cell Leukemia Treatment Market

血液肿瘤治疗

医药市场分析

Report of Hairy cell Leukemia Treatment Market is covering the summarized study of several factors encouraging the growth of the market such as market size, market type, major regions and end user app

IMR REPORTS60

DataSheet_1_Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.docx

血液肿瘤治疗

造血干细胞移植前桥接疗法

IntroductionDespite high cure rates with standard treatment, 30% patients with Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell

NIAID Data Ecosystem40

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

资源简介：

相关数据集